Cencora (COR) DIvidends Date & History

Key Takeaways

• Cencora offers a trailing dividend yield of 0.73% and forward yield of 0.79%, paid quarterly at $0.60 per share.
• The payout ratio stands at 27%, indicating ample room for growth and sustainability.
• Free cash flow payout ratio is approximately 13%, supported by robust cash generation exceeding $3 billion annually.
• Dividend has shown steady growth, with a 3-year growth rate of 6.1% and recent increases to $0.60 per share.
• Compared to peers like MCK (0.4% yield) and CAH (1.0% yield), COR's yield is competitive in pharmaceutical distribution.
• Recent ex-dividend date was February 13, 2026, with payment on March 2, 2026.

Dividend Overview

Cencora, Inc. (COR), a leading global pharmaceutical distributor, maintains a modest dividend profile suited to its growth-oriented business model. The company pays a quarterly dividend of $0.60 per share, equating to an annual forward dividend of $2.40 and a trailing yield of 0.73% based on recent stock prices around $304. The forward yield is 0.79%, reflecting anticipated stability. Over the past five years, the average yield has been 1.02%, positioning COR as neither a high-yield play nor a pure growth stock but a balanced dividend payer in the healthcare distribution sector. This policy supports reinvestment in operations while rewarding shareholders consistently.

Dividend History and Growth

Cencora has a long history of dividend payments, tracing back decades as a consistent payer in the pharmaceutical wholesale industry. Recent quarters show quarterly payouts of $0.60, up from prior levels such as $0.55 announced in late 2024. The 3-year dividend growth rate stands at 6.1%, reflecting steady increases amid earnings expansion of 14% annually over five years. While not a Dividend Aristocrat with 25+ consecutive years of raises, the company has avoided cuts and prioritized growth, aligning with its strategy to fund acquisitions and operational expansion in specialty pharmaceuticals and global distribution.

Dividend Sustainability and Payout Ratio

Cencora's dividend appears highly sustainable, with a payout ratio of 27.01% of earnings, leaving significant room for reinvestment or future hikes. Free cash flow coverage is even stronger at around 12.55%, backed by annual FCF exceeding $3 billion in recent years. Moderate debt levels and stable cash flows from its essential role in drug distribution further bolster reliability. Earnings growth and low payout metrics suggest the dividend is well-covered, with capacity for continued modest increases.

Dividend Compared to Industry Peers

In the pharmaceutical distribution sector, Cencora's 0.73-0.79% yield sits between peers. McKesson (MCK) offers a lower 0.4% yield, emphasizing growth over income, while Cardinal Health (CAH) provides about 1.0%, appealing more to yield seekers. Henry Schein (HSIC), another distributor, currently yields 0%. COR's profile stands out for its balance of yield, growth, and coverage relative to these competitors.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to enhance your stock selection process today.

Is This Stock Attractive for Dividend Investors?

Cencora (COR) may appeal to dividend growth investors seeking modest yields with strong sustainability in a defensive sector. Its low payout ratio and robust free cash flow make it suitable for those prioritizing long-term compounding over high immediate income. Conservative investors could value the stability from recurring pharmaceutical distribution revenues, which buffer economic cycles. However, yield-focused investors might look elsewhere for higher payouts, as COR's 0.8% yield trails some utilities or REITs. Balanced portfolios blending growth and income may find COR's profile fitting, given its earnings momentum and peer-competitive stance. Overall, it suits patient investors focused on healthcare exposure with reliable, growing dividends rather than top-tier yields.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations